Heart Failure with Preserved Ejection Fraction (HFpEF) Pipeline Summary

DelveInsight’s, “Heart Failure with Preserved Ejection Fraction (HFpEF) - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Heart Failure with Preserved Ejection Fraction (HFpEF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Heart Failure with Preserved Ejection Fraction (HFpEF): Understanding

Heart Failure with Preserved Ejection Fraction (HFpEF): Overview

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome characterized by the presence of heart failure symptoms and signs despite a left ventricular ejection fraction (LVEF) ?50%, primarily due to impaired ventricular relaxation and increased myocardial stiffness. HFpEF accounts for approximately half of all heart failure cases and is particularly common among older adults, women, and individuals with hypertension, obesity, diabetes mellitus, chronic kidney disease, atrial fibrillation, and coronary artery disease.

Patients typically present with exertional dyspnea, fatigue, reduced exercise tolerance, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and pulmonary congestion. The condition is associated with frequent hospitalizations, impaired quality of life, and mortality rates comparable to those observed in heart failure with reduced ejection fraction.

The pathophysiology of HFpEF is driven by diastolic dysfunction, in which impaired myocardial relaxation and increased ventricular stiffness elevate left ventricular filling pressures despite preserved systolic function. Systemic inflammation associated with aging and comorbidities contributes to endothelial dysfunction, myocardial fibrosis, microvascular rarefaction, and adverse cardiac remodeling, leading to impaired ventricular compliance and reduced cardiac reserve during exercise.

Diagnosis is based on compatible symptoms and signs of heart failure, preserved LVEF (?50%), and objective evidence of elevated left ventricular filling pressures or structural heart disease. Transthoracic echocardiography is the primary diagnostic modality for assessing diastolic function, left atrial enlargement, and ventricular hypertrophy, while measurement of BNP or NT-proBNP, electrocardiography, cardiac magnetic resonance imaging, and exercise or invasive hemodynamic testing may be used to support diagnosis in uncertain cases.

Management of HFpEF focuses on alleviating symptoms, reducing hospitalizations, treating underlying comorbidities, and improving functional status. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin and dapagliflozin, are recommended to reduce the risk of cardiovascular death and heart failure hospitalization across the HFpEF spectrum. Diuretics are used to relieve congestion, while blood pressure control, management of atrial fibrillation, coronary artery disease, obesity, diabetes, chronic kidney disease, and sleep apnea are essential components of therapy. Selected patients may benefit from mineralocorticoid receptor antagonists or angiotensin receptor–neprilysin inhibitors (ARNIs), particularly those with mildly reduced or borderline preserved ejection fraction. Lifestyle interventions, including regular exercise training, dietary optimization, weight management, cardiac rehabilitation, and routine follow-up, remain fundamental to improving quality of life and long-term clinical outcomes.

"Heart Failure with Preserved Ejection Fraction (HFpEF)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure with Preserved Ejection Fraction (HFpEF) pipeline landscape is provided which includes the disease overview and Heart Failure with Preserved Ejection Fraction (HFpEF) treatment guidelines. The assessment part of the report embraces, in depth Heart Failure with Preserved Ejection Fraction (HFpEF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure with Preserved Ejection Fraction (HFpEF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure with Preserved Ejection Fraction (HFpEF) R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure with Preserved Ejection Fraction (HFpEF) Emerging Drugs Chapters

This segment of the Heart Failure with Preserved Ejection Fraction (HFpEF) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart Failure with Preserved Ejection Fraction (HFpEF) Emerging Drugs

Maridebart cafraglutide: Amgen

Maridebart cafraglutide (MariTide; AMG 133) is an investigational, once-monthly GLP-1 receptor agonist/GIP receptor antagonist peptide–antibody conjugate being developed by Amgen for patients with HFpEF or HFmrEF and obesity. By promoting substantial weight loss and improving cardiometabolic and inflammatory pathways, it aims to reduce the burden of obesity-driven heart failure while improving functional status. The global Phase III MARITIME-HF trial is evaluating maridebart cafraglutide as an adjunct to standard of care for its effects on cardiovascular death, heart failure hospitalizations, urgent HF visits, symptoms, and quality of life.

VS-041: Vasa Therapeutics

VS-041 is an investigational oral small-molecule matrix metalloproteinase (MMP) inhibitor being developed for the treatment of heart failure with preserved ejection fraction (HFpEF). It is designed to target pathological extracellular matrix remodeling and fibrosis, aiming to improve myocardial structure and function rather than providing only symptomatic relief. VS-041 is currently being evaluated in the randomized Phase I VS-041-102 trial, which is assessing its safety, tolerability, pharmacokinetics, and effects on fibrosis-related biomarkers in patients with HFpEF.

Further product details are provided in the report……..

Heart Failure with Preserved Ejection Fraction (HFpEF): Therapeutic Assessment

This segment of the report provides insights about the different Heart Failure with Preserved Ejection Fraction (HFpEF) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Heart Failure with Preserved Ejection Fraction (HFpEF)
• There are approx. 10+ key companies which are developing the therapies for Heart Failure with Preserved Ejection Fraction (HFpEF). The companies which have their Heart Failure with Preserved Ejection Fraction (HFpEF) drug candidates in the most advanced stage, i.e. Phase III include, Amgen.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Heart Failure with Preserved Ejection Fraction (HFpEF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart Failure with Preserved Ejection Fraction (HFpEF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Heart Failure with Preserved Ejection Fraction (HFpEF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure with Preserved Ejection Fraction (HFpEF) drugs.

Heart Failure with Preserved Ejection Fraction (HFpEF) Report Insights

• Heart Failure with Preserved Ejection Fraction (HFpEF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Heart Failure with Preserved Ejection Fraction (HFpEF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Heart Failure with Preserved Ejection Fraction (HFpEF) drugs?
• How many Heart Failure with Preserved Ejection Fraction (HFpEF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure with Preserved Ejection Fraction (HFpEF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Heart Failure with Preserved Ejection Fraction (HFpEF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amgen
• Medera Group
• GSK
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Vasa Therapeutics
• Secretome Therapeutics
• Bristol-Myers Squibb
• Novo Nordisk

Key Products

• Maridebart cafraglutide
• SRD-1002
• GSK6792070
• HRS-1893
• VS-041
• STM01
• MYK-224
• CDR132L